{
    "url_original": "https://www.wsj.com/articles/perkinelmer-buying-antibodies-maker-biolegend-for-5-25-billion-11627305156?mod=business_lead_pos4",
    "url": "perkinelmer-buying-antibodies-maker-biolegend-for-5-25-billion-11627305156",
    "title": "PerkinElmer Buying Antibodies Maker BioLegend for $5.25 Billion",
    "sub_head": "BioLegend’s San Diego campus to become center for research reagent content development for combined company",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-375069?width=860&height=573",
    "image_1": "im-375069.jpg",
    "time": "2021-07-26 09:12:00",
    "body": "PerkinElmer Inc.  said it is buying BioLegend, which provides life science antibodies and reagents, for $5.25 billion in a combination of cash and stock.<br />PerkinElmer said Monday the transaction is expected to close by the end of the 2021 calendar year.<br />Privately held BioLegend has more than 700 employees based primarily in the U.S., with estimated 2022 revenues of $380 million, PerkinElmer said.<br />Upon joining PerkinElmer, BioLegend’s San Diego campus will become PerkinElmer’s global Center of Excellence for research reagent content development for the combined company.<br />The deal is expected to boost PerkinElmer’s existing revenue growth and profit margin profile, and add an estimated 30 cents of adjusted earnings a share in the first full year after closing the deal, and greater than 50 cents in the second year after closing."
}